Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

The rash resolved after stopping ponatinib.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Gefitinib therapy can cause unusual hair growth on the nose.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

ZD1839 can cause skin issues like acne and hair changes.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Quercitrin may help treat Alzheimer's by boosting brain cell signaling without causing tumors.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.